168 related articles for article (PubMed ID: 28147308)
21. In vitro and in vivo anti-tumor effects of selected platinum(IV) and dinuclear platinum(II) complexes against lung cancer cells.
Arsenijevic M; Milovanovic M; Jovanovic S; Arsenijevic N; Markovic BS; Gazdic M; Volarevic V
J Biol Inorg Chem; 2017 Aug; 22(6):807-817. PubMed ID: 28421385
[TBL] [Abstract][Full Text] [Related]
22. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
23. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
[TBL] [Abstract][Full Text] [Related]
24. Glucose conjugated platinum(II) complex: antitumor superiority to oxaliplatin, combination effect and mechanism of action.
Li H; Gao X; Liu R; Wang Y; Zhang M; Fu Z; Mi Y; Wang Y; Yao Z; Gao Q
Eur J Med Chem; 2015 Aug; 101():400-8. PubMed ID: 26177447
[TBL] [Abstract][Full Text] [Related]
25. A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines.
Shahsavar F; Bozorgmehr M; Mirzadegan E; Abedi A; Lighvan ZM; Mohammadi F; Safari N; Amani V; Zarnani AH
Anticancer Agents Med Chem; 2016; 16(3):393-403. PubMed ID: 26899296
[TBL] [Abstract][Full Text] [Related]
26. Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.
Hoffmeister BR; Hejl M; Adib-Razavi MS; Jakupec MA; Galanski M; Keppler BK
Chem Biodivers; 2015 Apr; 12(4):559-74. PubMed ID: 25879501
[TBL] [Abstract][Full Text] [Related]
27. In vitro biological evaluation of platinum(II) complexes with 1-(methoxy substituted benzyl) azetidine-3,3-dicarboxylato ligands.
Yin R; Gou S; Sun Y; Liu X
Bioorg Med Chem; 2012 Feb; 20(4):1461-7. PubMed ID: 22264764
[TBL] [Abstract][Full Text] [Related]
28. Antitumor platinum(II) complexes of N-monoalkyl-1R, 2R-diaminocyclohexane derivatives with alkyl groups as hindrance.
Sun Y; Yin R; Gou S; Zhaojian
J Inorg Biochem; 2012 Jul; 112():68-76. PubMed ID: 22561544
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, antiproliferative activity and DNA binding study of mixed ammine/cyclohexylamine platinum(II) complexes with 1-(substituted benzyl) azetidine-3, 3-dicarboxylates.
Sun Y; Gou S; Yin R; Jiang P
Eur J Med Chem; 2011 Oct; 46(10):5146-53. PubMed ID: 21875765
[TBL] [Abstract][Full Text] [Related]
30. Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity.
Starha P; Trávnícek Z; Popa I
J Inorg Biochem; 2010 Jun; 104(6):639-47. PubMed ID: 20304500
[TBL] [Abstract][Full Text] [Related]
31. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).
Kizu R; Nakanishi T; Hayakawa K; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Tashiro T; Kidani Y
Cancer Chemother Pharmacol; 1999; 43(2):97-105. PubMed ID: 9923814
[TBL] [Abstract][Full Text] [Related]
32. Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.
Yu H; Gou S; Wang Z; Chen F; Fang L
Eur J Med Chem; 2016 May; 114():141-52. PubMed ID: 26974381
[TBL] [Abstract][Full Text] [Related]
33. Monofunctional platinum(II) complexes with potent tumor cell growth inhibitory activity: the effect of a hydrogen-bond donor/acceptor N-heterocyclic ligand.
Margiotta N; Savino S; Gandin V; Marzano C; Natile G
ChemMedChem; 2014 Jun; 9(6):1161-8. PubMed ID: 24799414
[TBL] [Abstract][Full Text] [Related]
34. Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents.
Xiao H; Qi R; Li T; Awuah SG; Zheng Y; Wei W; Kang X; Song H; Wang Y; Yu Y; Bird MA; Jing X; Yaffe MB; Birrer MJ; Ghoroghchian PP
J Am Chem Soc; 2017 Mar; 139(8):3033-3044. PubMed ID: 28166401
[TBL] [Abstract][Full Text] [Related]
35. N-Heterocyclic Carbene-Polyethylenimine Platinum Complexes with Potent in Vitro and in Vivo Antitumor Efficacy.
Chekkat N; Dahm G; Chardon E; Wantz M; Sitz J; Decossas M; Lambert O; Frisch B; Rubbiani R; Gasser G; Guichard G; Fournel S; Bellemin-Laponnaz S
Bioconjug Chem; 2016 Aug; 27(8):1942-8. PubMed ID: 27459208
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
[TBL] [Abstract][Full Text] [Related]
37. Potent anticancer activity and possible low toxicity of platinum(II) complexes with functionalized 1,1-cyclobutanedicarboxylate as a leaving ligand.
Zhao J; Gou S; Liu F
Chemistry; 2014 Nov; 20(46):15216-25. PubMed ID: 25256173
[TBL] [Abstract][Full Text] [Related]
38. New Oxaliplatin-Pyrophosphato Analogs with Improved In Vitro Cytotoxicity.
Barbanente A; Iacobazzi RM; Azzariti A; Hoeschele JD; Denora N; Papadia P; Pacifico C; Natile G; Margiotta N
Molecules; 2021 Jun; 26(11):. PubMed ID: 34200051
[TBL] [Abstract][Full Text] [Related]
39. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
[TBL] [Abstract][Full Text] [Related]
40. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
